YourVaccx™ – ImmunSYS, Inc.
ImmunSYS™ is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with late-stage metastatic prostate cancer and other metastatic adenocarcinomas.

Our platform technology, YourVaccx™ utilizes a novel combination of the proprietary ANTIGENerator™ energy delivery device system, a proprietary branded formulation of immunotherapeutic drugs, and a proprietary procedure developed by the focal prostate cancer therapy pioneer and inventor of the male lumpectomy, Gary Onik, M.D. 

The new YourVaccx™ immunotherapy is designed to empower the immune system to recognize and selectively attack cancer throughout the body. We are developing this radically new operating system for immunotherapy initially for the treatment of late-stage metastatic prostate cancer with a pipeline of additional development programs for other late-stage metastatic cancers.

Currently, there is a large unmet need in the treatment of late-stage metastatic prostate cancer.  Approximately 11.2 percent of men will be diagnosed with prostate cancer at some point during their lifetime.[1]     According to the National Cancer Institute, metastatic prostate cancer increased from 7.8 new cases per 100,000 in 2010, to 9.2 new cases per 100,000 in 2014.[1]   Despite advances in screening, early detection, and treatments, prostate cancer deaths are on the rise in the U.S.[2]   


2018 Estimated Deaths in U.S. from Prostate Cancer[3]

[1] National Cancer Institute. Cancer Stat Facts: Prostate Cancer.  Accessed online 24 May 2018

[2] Thompson D.  U.S. Cancer Death Rate Down, But Prostate Cases Up. HealthDay Reporter.  Accessed  online 24 May 2018

[3]American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018.

YourVaccx™ Animation

The animation below provides a brief overview of how YourVaccx™ works to fight cancer.

Disclaimers: The content on this website is intended for US healthcare professionals only. YourVaccx™ and any other trade names mentioned in this website are not approved by the US Food and Drug Administration.

The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.

YourVaccx™ Therapy: A Closer Look

The cancer immunotherapy utilizes a three-step process to deliver a novel therapeutic treatment:


Antigen Exposure

A probe is placed into the target tumor and the ANTIGENerator™ device is utilized to deliver energy into a portion of the tumor (treatment zone). This device is able to disrupt cancer cell membranes in a way that does not damage the complex antigen structures, while preserving the critical fluid pathways that the immune system requires to optimally function.

Disruption of the cell membrane liberates its contents, including antigens, which are then presented to the immune system.

ANTIGENerator energy delivery system


Immunotherapy is Delivered

A branded immunotherapy formulation is then injected directly into the treatment zone created by the ANTIGENerator. This injection performs multiple functions. 

  • First, it forces the newly exposed cancer antigens into the tissue drainage system (lymphatic system) and into contact with the immune system. 
  • Second, the formulation works to mitigate the cancer’s ability to locally block immune responses against the newly exposed cancer antigens
  • Lastly, the immune system is “turbo charged” with immuno-stimulatory drugs to ramp up the immune system to better fight the cancer.
Delivery of immunotherapy into treatment zone


Immune System Attacks Cancer Throughout Body

These three functions work to enable the immune system to recognize the cancer and create an autologous therapeutic vaccine which is derived from the patient’s own tumor cell antigens.

This vaccine then travels throughout the body to attack the cancer.


Immune system attacks cancer throughout the body